The patent cliff - more of a gentle slope?
This article was originally published in Scrip
Executive Summary
If the pundits are to be believed, the period between now and 2012 is set to be make-or-break time for the pharmaceutical industry, as a number of major products come off-patent. At risk are products such as Pfizer’s Lipitor (atorvastatin), Lilly’s Zyprexa (olanzapine), AstraZeneca’s Seroquel (quetiapine), and Sanofi-Aventis/ Bristol-Myers Squibb’s Plavix (clopidogrel).